- Price
- $149.78
- Day
- +1.85%
- Mkt Cap
- $8.45B
- 52W Range
- $100.99 – $175.77
- Volume
- 1.20M
- Beta
- 1.06
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Avidity Partners Management LP increased its position in shares of Repligen Corporation (NASDAQ: RGEN) by 54.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,800 shares of the biotechnology company's stock after acquiring an additional 27,500
Read full article
The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read full article
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
Read full article
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Read full article
Repligen (RGEN) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.37 per share a year ago.
Read full article
Repligen NASDAQ: RGEN reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted earnings outlook, citing continued order momentum and improved visibility into the second half.
Read full article
WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2026, covering the three-month period ended June 30, 2026. The Company is also providing updated financial guidance for the full year 2026.
Read full article
American Capital Management Inc. increased its position in shares of Repligen Corporation (NASDAQ: RGEN) by 6.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 357,720 shares of the biotechnology company's stock after purchasing an additional 22,605 shares during the
Read full article
First Trust Advisors LP raised its position in Repligen Corporation (NASDAQ: RGEN) by 122.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 630,070 shares of the biotechnology company's stock after purchasing an additional 347,294 shares during the quarter. First
Read full article
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whe.
Read full article
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
Read full article
Repligen Corporation (RGEN) M&A Call Transcript
Read full article